To understand cancer drug discovery and development through a range of lectures, panel discussions and case studies.
|09:30 to 10:00||Registration and Refeshments|
|10:00 to 10:05||Welcome
Professor Duncan Jodrell, EMIT, University of Cambridge
|10:00 to 10:30||Introduction to the drug development paradigm
Andrew Foxley, Senior Director Scientific Project Management Oncology Translational Medicine Unit, Early Clinical Development Innovative Medicines, AstraZeneca
|10:30 to 10:55||Cell Therapy Target Validation and “Hit ID” in Oncology
Dr Mark Creighton-Gutteridge, Director, Head of Discovery and New Technologies, Oncology Cell Therapy R&D, GlaxoSmithKline. Recommended Reading: GOTTSCHALK ET AL. CANCER J. 2014; 20(2): 151–155. DOI:10.1097/PPO.0000000000000032
|10:55 to 11:20||Pre-clinical development (toxicology/PK/PD)
James Yates Principal Scientist applying Quantitative Systems Pharmacology at AstraZeneca
|11:20 to 11:45||Pharmacological Audit Trail in Cancer Drug Development
Dr Simon Pacey, Clinical Senior Research Associate Academic Consultant in Cancer Therapeutics, Department of Oncology, University of Cambridge. Reading: Critical parameters in targeted drug development: the pharmacological audit trail. Banerji and Workman. Semin Oncol 2016 https://www.ncbi.nlm.nih.gov/pubmed/27663475
|11:45 to 12:15||Panel discussion|
|12:15 to 13:30||Lunch and student posters|
|13:30 to 14:00||Adaptive Trial Design
Dr Steven Fox, Principal Statistician, ECD Biometrics Oncology, AstraZeneca
|14:00 to 14:30||Drug combinations
Professor Duncan Jodrell, Professor of Cancer Therapeutics Director Cambridge Cancer Trials Centre (CCTC), Department of Oncology, University of Cambridge
|14:30 to 14:50||Imaging biomarkers of treatment response: from RECIST to functional and molecular imaging
Dr Ferdia Gallagher, Cancer Research UK Clinician Scientist Fellow, Reader in Molecular Imaging, Department of Radiology University of Cambridge. Recommended Reading: Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol. 2017 Mar;14(3):169-186.
|14:50 to 15:15||Panel discussion|
|15:15 to 15:45||Break|
|15:45 to 16:05||The immuno-oncology revolution: A clinical overview
Dr Au Lewis, Translational Research Scientist, Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute.
|16:00 to 16:25||A Case Study: Durvalumab
Dr Robert Wilkinson, Director, Oncology Research, AstraZeneca
|16:25 to 16:45||Immuno-oncology combinations
Dr Simon Dovedi, Group Leader Immuno-oncology, AstraZeneca & Honorary Senior Visiting Fellow in the Department of Oncology, University of Cambridge.
|16:45 to 17:30||Panel discussion and closing remarks|
|17:30 to 19:00||Drinks reception|
|19:00 to 22:30||Dinner|
Renal Drug Discovery and Development